	US 12,234,513 B2
	Methods for assessing risk of developing a viral disease using a genetic test
Eli Hatchwell, Winchester (GB); Peggy S. Eis, Fitchburg, WI (US); Edward B. Smith, III, New York, NY (US); and Yassine Taoufik, Paris (FR)
Assigned to PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Yvette (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Medicale (INSERM), Paris (FR)
Filed by PML Screening, LLC, Newport Beach, CA (US); Université Paris-Saclay, Gif sur Yvette (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed on Apr. 25, 2024, as Appl. No. 18/645,942.
Application 18/645,942 is a division of application No. 17/161,171, filed on Jan. 28, 2021, granted, now 12,054,778.
Application 17/161,171 is a division of application No. 16/602,348, filed on Aug. 15, 2019, granted, now 10,961,585, issued on Mar. 30, 2021.
Application 16/602,348 is a continuation of application No. PCT/US2019/045721, filed on Aug. 8, 2019.
Claims priority of provisional application 62/716,072, filed on Aug. 8, 2018.
Claims priority of provisional application 62/716,183, filed on Aug. 8, 2018.
Prior Publication US 2024/0287611 A1, Aug. 29, 2024
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01)

CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)]

30 Claims

1. A method of treating a condition in a subject in need of immunosuppressive therapy, comprising: administering a therapeutically effective amount of an immunosuppressive agent to the subject, wherein the immunosuppressive agent has a potential to induce progressive multifocal leukoencephalopathy (PML) due to a John Cunningham virus (JCV) infection, wherein:

(i) when the subject has been identified as not having one or more genetic variations that disrupt or modulate a C8B gene, a FCN2 gene, or a LY9 gene, the administering is based on the subject having been identified as not having the one or more genetic variations; and

(ii) when the subject has been identified as having one or more genetic variations that disrupt or modulate a C8B gene, a FCN2 gene, or a LY9 gene, the potential of the immunosuppressive agent to induce PML is known to be higher when administered to a subject having the one or more genetic variations compared to the potential of the immunosuppressive agent to induce PML when administered to a subject not having the one or more genetic variations; and

wherein the immunosuppressive agent comprises cladribine.